Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aveo Pharmaceuticals (AVEO)

Aveo Pharmaceuticals (AVEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aveo Pharmaceuticals ONE BROADWAY 14TH FLOOR CAMBRIDGE MA 02142 USA

P: 617-588-1960 F: 617-621-1406

Description:

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 113,067
Shares Outstanding, K 160,744
Annual Sales, $ 5,410 K
Annual Net Income, $ -5,330 K
Last Quarter Sales, $ 25,720 K
Last Quarter Net Income, $ 16,430 K
60-Month Beta 0.70
% of Insider Shareholders 3.80%
% of Institutional Shareholders 26.63%
Float, K 154,636
% Float 96.20%

Growth:

1-Year Return -65.85%
3-Year Return 23.40%
5-Year Return -17.25%
5-Year Revenue Growth 319.38%
5-Year Earnings Growth 90.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/08/19
Earnings Per Share ttm -0.01
EPS Growth vs. Prev Qtr 600.00%
EPS Growth vs. Prev Year 300.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

AVEO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -11.60
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -561.43
Return-on-Assets (Before Tax) 91.54
Profit Margin % -98.52
Net Margin % 28.43
Debt/Equity 6.84
Price/Sales 20.98
Price/Cash Flow N/A
Price/Book 6.05
Book Value/Share 0.12
Interest Coverage -1.43
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar